Hyderabad, January 9: Ocugen Inc., Bharat Biotech’s partner for US and Canada for COVID-19 vaccine Covaxin (BBV152) on Monday said it got positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of the jab in US.
A press release from the US biopharmaceutical company said the study enrolled 419 US adult participants that were randomized 1:1 to receive two doses of Covaxin or placebo, 28 days apart. Covaxin Regulatory Approval Was Rushed Due to Political Pressure? Government Terms Media Reports About COVID-19 Vaccine ‘Misleading and Fallacious’.
“The successful completion of this study represents an important milestone to the ongoing management of COVID-19. Given that a portion of the public remains hesitant to receive mRNA vaccines, this investigational COVID-19 vaccine candidate, which relies on a well-established approach to vaccine development and manufacturing, may provide an important additional vaccine option,” Shankar Musunuri, Chairman and CEO of Ocugen said. COVID-19 in India: Bharat Biotech’s ‘Covaxin’ Gets Emergency Use Authorisation for Children Between 6-12 Years.
Immunogenicity results from Covaxin-vaccinated participants in US were compared with results in Covaxin-vaccinated participants in the Bharat Biotech-sponsored Phase 3 study in India.
Approximately 24 per cent of tested participants in US were vaccine-naive while all participants in the Bharat Biotech Phase 3 study were vaccine-naïve, it said.
The top-line data from the immuno-bridging and broadening study will be critical to support Ocugen’s future plans for the development of Covaxin in US, the release added.
(This is an unedited and auto-generated story from Syndicated News feed, Today News 24 Staff may not have modified or edited the content body)
//vdo (function(v,d,o,ai){ai=d.createElement('script');ai.defer=true;ai.async=true;ai.src=v.location.protocol+o;d.head.appendChild(ai);})(window, document, '//a.vdo.ai/core/latestly/vdo.ai.js');
//colombai try{ (function() { var cads = document.createElement("script"); cads.async = true; cads.type = "text/javascript"; cads.src = "https://static.clmbtech.com/ase/80185/3040/c1.js"; var node = document.getElementsByTagName("script")[0]; node.parentNode.insertBefore(cads, node); })(); }catch(e){}
} });